白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察

doi:10.19401/j.cnki.1007-3639.2020.08.011

中国癌症杂志 ›› 2020, Vol. 30 ›› Issue (8): 632-635.doi: 10.19401/j.cnki.1007-3639.2020.08.011

白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察

颜　芳，应明真，陈龙佩，傅　强

海军军医大学附属长海医院肿瘤科，上海 200433

出版日期:2020-08-30 发布日期:2020-09-04
通信作者: 傅强 E-mail: fumaye71@163.com

Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients

YAN Fang, YING Mingzhen, CHEN Longpei, FU Qiang

Department of Oncology, Changhai Hospital, Shanghai 200433, China

Published:2020-08-30 Online:2020-09-04
Contact: FU Qiang E-mail: fumaye71@163.com

摘要/Abstract

摘要： 背景与目的：化疗是晚期食管癌患者的主要治疗手段，但目前尚没有标准的一线治疗方案，通过白蛋白结合型紫杉醇联合奈达铂方案治疗晚期食管癌，评价其临床疗效及安全性。方法：收集2016年2月—2019年2月之间在长海医院诊治的晚期食管癌并有可评价病灶的患者31例，一线予以白蛋白结合型紫杉醇联合奈达铂方案化疗，具体用药为：白蛋白结合型紫杉醇130 mg/m ² ，第1、8天；奈达铂70 mg/m² ，第1天；每3周重复。采用实体瘤疗效评价标准（Response Evaluation Criteria in Solid Tumors，RECIST）1.1标准评估疗效，按照美国国立癌症研究所通用毒性标准（National Cancer Institute Common Toxicity Criteria，NCI-CTC）5.0评估不良反应。结果：全部31例患者均可评价疗效，其中完全缓解（complete response，CR）1例（3.2%），部分缓解（partial response，PR）20例（64.5%），疾病稳定（stable disease，SD）9例（29.0%），疾病进展（progressive disease，PD）1例（3.2%），客观缓解率（objective response rate，ORR）为67.7%，疾病控制率（disease control rate，DCR）为96.8%，中位无进展生存期（progression-free survival，PFS）为9.4个月。常见不良反应主要包括骨髓抑制、感觉神经病变、关节酸痛、肌肉酸痛、消化道反应及脱发，无毒性相关死亡病例。结论：白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌疗效较好，不良反应患者可耐受，值得进一步推广。

关键词: 食管癌, 白蛋白结合型紫杉醇, 奈达铂, 化学治疗

Abstract: Background and purpose: Chemotherapy remains the main treatment method for metastatic esophageal squamous cell carcinoma (ESCC). However, no standard regimen has been established as first-line therapy for metastatic ESCC. The purpose of this study was to observe the clinical efficacy and safety of albumin-bound paclitaxel plus nedaplatin as first-line therapy in patients with metastatic ESCC. Methods: Clinical outcomes of 31 patients with metastatic ESCC in Changhai Hospital between Feb. 2016 and Feb. 2019 were analyzed. These patients received albumin-bound paclitaxel combined with nedaplatin as first-line therapy. Albumin-bound paclitaxel was administered at a dose of 130 mg/m² on day 1 and 8 of a 21-day cycle. Nedaplatin was administered at a dose of 70 mg/m ² on day 1 of a 21-day cycle. Evaluation of tumor response was performed according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Toxicities were graded using version of the National Cancer Institute Common Toxicity Criteria (NCI-CTC) 5.0. Results: All patients were available for evaluation. Of the 31 patients, 1 case (3.2%) got complete response (CR), 20 cases (64.5%) got partial response (PR), 9 cases (29.0%) had stable disease (SD) and 1 case (3.2%) had progressive disease (PD). The objective response rate (ORR) was 67.7%, the disease control rate (DCR) was 96.8% and the median progression-free survival (PFS) was 9.4 months. The main toxicities included hematological toxicity, sensory neuropathy, arthralgia, myalgia, gastrointestinal reactions and alopecia. Conclusion: The combination of albumin-bound paclitaxel and nedaplatin is found to be an effective and tolerable option as first-line therapy for patients with metastatic ESCC.

Key words: Esophageal squamous cell carcinoma, Albumin-bound paclitaxel, Nedaplatin, Chemotherapy

颜　芳, 应明真, 陈龙佩, 傅　强. 白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察[J]. 中国癌症杂志, 2020, 30(8): 632-635.

YAN Fang, YING Mingzhen, CHEN Longpei, FU Qiang. Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients[J]. China Oncology, 2020, 30(8): 632-635.

[1]	陈劭赓, 何荣琦, 张万飞, 林贤钻, 陈河山, 许荣誉. miR-122-5p通过靶向CREB1抑制食管癌细胞及移植瘤的生长[J]. 中国癌症杂志, 2021, 31(1): 35-44.
[2]	唐曦平, 刘爱群, 刘立义, 黄月丽. 胃镜检查在下咽癌共病食管癌中的重要性评价及其临床特点分析[J]. 中国癌症杂志, 2020, 30(8): 626-631.
[3]	雷海科, 廖忠莉, 李小升, 周　琦, 赵玉兰, 何　美, 陈伟庆, 周　宏, 张　维, 吴永忠 . 重庆市食管癌患者生存随访调查及预后影响因素研究[J]. 中国癌症杂志, 2020, 30(2): 98-105.
[4]	晋瑞,金迎迎,王敏聪,惠文涛,李毅,李芳,贾辉,潘继元,马红兵 . 抑制USP9x表达增强食管癌Ec9706-R细胞的放射敏感性[J]. 中国癌症杂志, 2019, 29(7): 486-493.
[5]	李文成，王孝深. 铂类药物在头颈部鳞癌治疗中的选择与应用[J]. 中国癌症杂志, 2019, 29(4): 300-306.
[6]	宋玉芝,吴晓琳,甄婵军,等. 99例结外NK/T细胞淋巴瘤预后分析[J]. 中国癌症杂志, 2018, 28(9): 698-705.
[7]	胡文斌,张　婷,秦　威,等. 江苏省昆山市1981—2015年去食管癌死因期望寿命和潜在减寿年分析[J]. 中国癌症杂志, 2018, 28(4): 263-269.
[8]	徐　瞳,胡丽娜,郭显智,等. 5-氮杂胞苷可通过抑制Notch1通路诱导食管癌细胞凋亡[J]. 中国癌症杂志, 2018, 28(10): 726-732.
[9]	曹燕飞,任　睿,杨　晔,等. LRRC3B对食管癌细胞Eca109迁移、侵袭及PI3K/Akt信号通路的影响[J]. 中国癌症杂志, 2017, 27(5): 345-352.
[10]	刘志坤,张魏丽,祝淑钗,等. 慢病毒介导沉默食管癌细胞53BP1基因表达对裸鼠移植瘤放射敏感性的研究[J]. 中国癌症杂志, 2016, 26(7): 574-580.
[11]	温仁祝,陈铭伍,冼　磊,等. 食管癌术后吻合口狭窄预防方法的探讨[J]. 中国癌症杂志, 2016, 26(6): 552-555.
[12]	刘　琪,余　雯,蔡旭伟,等. PET-CT用于评价食管鳞癌放疗中¹⁸F-FDG高摄取区域的空间动态变化的前瞻性研究[J]. 中国癌症杂志, 2016, 26(2): 161-167.
[13]	陈　赟,艾沓杉,夏　怡,等. 紫杉醇联合氟尿嘧啶同期放疗治疗初治局部晚期食管鳞癌患者的Ⅱ期临床研究[J]. 中国癌症杂志, 2016, 26(11): 926-931.
[14]	何　丹,刘　翼,吴振华,等. 胸腹腔镜与传统开放手术治疗食管癌的围手术期疗效对比[J]. 中国癌症杂志, 2016, 26(11): 932-938.
[15]	金　波,张岩巍,韩宝惠,等. EGFR敏感突变的晚期肺腺癌一线化疗与吉非替尼联合治疗的随机对照研究[J]. 中国癌症杂志, 2015, 25(10): 761-767.

白蛋白结合型紫杉醇联合奈达铂一线治疗晚期食管癌患者的临床观察

Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价